Abstract
Background: Direct oral anticoagulants (DOACs) constitute the pharmacological standard for stroke prevention in atrial fibrillation, yet a meaningful proportion of patients face contraindications, recurrent bleeding, or thromboembolic events despite treatment. Left Atrial Appendage Occlusion (LAAO) offers a device-based alternative, and this systematic review and meta-analysis aimed to compare the efficacy and safety of DOACs and LAAO for stroke prevention in atrial fibrillation. Methods: PubMed, Scopus, Embase, and the Cochrane Central Register of Controlled Trials were searched to December 2025 for randomized trials and propensity-matched cohorts directly comparing LAAO with DOACs. Six studies were included. Random-effects models with the DerSimonian and Laird estimator generated pooled Odds Ratios (ORs) for ischemic stroke, major bleeding, and all-cause mortality, expressed for LAAO relative to DOAC, with heterogeneity assessed using the I-squared statistic. Results: Ischemic stroke was numerically more frequent with LAAO without reaching significance (OR 1.44, 95% CI 0.86 to 2.42; I-squared 34%). Major bleeding was significantly lower with LAAO (OR 0.78, 95% CI 0.64 to 0.95; Isquared 12%), as was all-cause mortality (OR 0.82, 95% CI 0.72 to 0.93; I-squared 0%). The findings were consistent across the randomized and propensity matched evidence and reflect a coherent trade-off between thromboembolic protection and bleeding avoidance. Conclusion: Relative to DOACs, LAAO conferred comparable but possibly less complete protection against ischemic stroke, offset by significant reductions in major bleeding and all-cause mortality. These findings support LAAO as a reasonable alternative for selected patients unsuited to long-term anticoagulation, while underscoring the need for adequately powered randomized trials in the broader atrial fibrillation population.
Keywords: Atrial fibrillation, Left atrial appendage occlusion, Direct oral anticoagulants, Stroke prevention, Major bleeding, Meta-analysis